Prescription dual orexin receptor antagonist (DORA; Schedule IV controlled substance) approved for insomnia characterized by difficulty with sleep onset and/or sleep maintenance. Represents a novel mechanism for treating insomnia by blocking the wakefulness-promoting orexin (hypocretin) neuropeptide system rather than enhancing GABAergic inhibition. May preserve normal sleep architecture better than GABA-targeting hypnotics. Dosage must be determined by your prescribing physician.
Evidence rating moderate. Most-documented uses: improved sleep onset, improved sleep maintenance, novel non-gaba mechanism. 10 sources indexed (2015–2025), with 2 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Antagonizes both orexin receptor type 1 (OX1R) and type 2 (OX2R), blocking the binding of wake-promoting neuropeptides orexin-A and orexin-B. The orexin system plays a critical role in maintaining wakefulness; blocking these receptors reduces the wakefulness drive, facilitating the natural transition to sleep without directly enhancing inhibitory neurotransmission.6,8
Class
Sedative-Hypnotic (Orexin Receptor Antagonist)
Absorption
Fat-soluble; take with food
Dosing
Dosing & protocol.
Common range
10–20 mg at bedtime (as prescribed by your physician)
Recommended form
Tablet
Take within 30 minutes of going to bed, with at least 7 hours remaining before planned awakening. Taking with food delays onset. Avoid taking with or after a meal.
Alcohol can add to suvorexant-related sleepiness and impaired alertness. A clinical alcohol coadministration study found additive negative effects on psychomotor performance, balance, memory, and alertness. The risk is most relevant at bedtime, with higher suvorexant doses, or when next-day driving is required.
Recommendation: Avoid alcohol when taking suvorexant. Do not take suvorexant after evening drinking, and do not drive the next morning if you feel sleepy or slowed. Use extra caution if you are older or also take other sedating medicines.
Suvorexant exposure is sensitive to CYP3A modulation, and St. John's Wort can induce CYP3A4. Combining them may lower suvorexant levels and reduce sleep benefit; stopping St. John's Wort can then restore exposure and increase next-day sleepiness. The effect depends on the hyperforin content of the St. John's Wort product.
Recommendation: Avoid St. John's Wort while using suvorexant unless your prescriber approves. Do not raise suvorexant to overcome reduced effect from the herb. If St. John's Wort is stopped, monitor for stronger sedation and next-day impairment.
de Oliveira HM, Gallo Ruelas M, Zamora FV et al.. Efficacy of Ramelteon, Suvorexant, and Lemborexant for Delirium Prevention in Hospitalized Patients: A Systematic Review and Meta-Analysis. Critical care medicine. 2025
Tian Y, Qin Z, Han Y. Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. 2022
Adams AD, Pepin MJ, Brown JN. The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review. Journal of critical care. 2020
Kishi T, Matsunaga S, Iwata N. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. PloS one. 2015
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Suvorexant in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack